A Phase 1 interventional study of Descartes-11 and Fludarabine in Multiple Myeloma, sponsored by Cartesian Therapeutics. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Cartesian Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,168 studies in Multiple Myeloma with a site in United States — 273 open to participants now, 501 under way, 66 of them phase 3. Multiple Myeloma · United States.
Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,308th largest by enrollment of the 1,901 interventional ones that give a count, is one of 85 that started in 2019, is one of 559 in phase 1, and was the 1,544th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →273 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
PrECOG, LLC. · Sites in United States
Ages 18–79
CellCentric Ltd. · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 853 · Phase 2 1,052 · Phase 3 191 · Phase 4 14
First in 1975; this study’s year is marked. 85 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 36 across the 1,901 interventional studies, 154 across the 167 observational. Of the 1,537 that completed or were terminated, 726 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
689 of 2,168 have an industry lead sponsor. The 10 most frequent:
Cartesian Therapeutics is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Cartesian Therapeutics has 6 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
155 of the studies in Multiple Myeloma with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT01863550Phase 3ECOG-ACRIN Cancer Research GroupBortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | 2026-12-31 |
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT03823534Phase 3St. Louis UniversityPost-Op Pain Control for Prophylactic Intramedullary Nailing. | 2027-03-31 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
Add all 155 to your calendar (.ics) → With an account.
Among the 2,168 studies in Multiple Myeloma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 10 million cells of Descartes-11 via intravenous catheter on Days 7,14
Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide
Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 32 million cells of Descartes-11 via intravenous catheter on Days 7,14
Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide
Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 100 million cells of Descartes-11 via intravenous catheter on Days 7,14
Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide
Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 150 million cells of Descartes-11 via intravenous catheter on Days 7,14,21
Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide
Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 150 million cells of Descartes-11 via intravenous catheter on Days 7,10,14,21
Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide
Participants were not administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 150 million cells of Descartes-11 via intravenous catheter on Days 1,4, 7,10,14,21
Biological: Descartes-11
CAR T-Cells
Pre-conditioning chemotherapy
Pre-conditioning therapy
Number of Participants With Treatment-Related Adverse Events
Determine the safety of Descartes-11 in patients with relapsed/refractory multiple myeloma
Time frame: Time Frame: 21 days
Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria
Patience with Complete response (CR) according to the International Myeloma Working Group (IMWG).
Time frame: Disease assessment is on Day 21 (or at least 14 days after first Descartes-11 infusion)
| Milestone | Decartes-11 Dose Level 1 | Descates-11 Level 2 | Descartes-11 Dose Level 3 | Descartes-11 Dose Level 4A | Descartes-11 Dose Level 4B | Descartes-11 Dose Level 4C |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 2 | 4 | 4 |
| Completed | 3 | 4 | 3 | 2 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Determine the safety of Descartes-11 in patients with relapsed/refractory multiple myeloma
| Participants | Dose-Escalation Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4A | Dose Level 4B | Dose Level 4C |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Related Adverse Events | 0 | 1 | 1 | 0 | 0 | 0 |
Patience with Complete response (CR) according to the International Myeloma Working Group (IMWG).
| Participants | Dose-Escalation Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4A | Dose Level 4B | Dose Level 4C |
|---|---|---|---|---|---|---|
| Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Follow ups conducted on months 3,6,9,12.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) |
| Dose Level 2 | 1/4 (25%) | 2/4 (50%) | 2/4 (50%) |
| Dose Level 3 | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Dose Level 4A | 0/2 (0%) | 1/2 (50%) | 1/2 (50%) |
| Dose Level 4B | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Dose Level 4C | 1/4 (25%) | 0/4 (0%) | 2/4 (50%) |
| Event | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4A | Dose Level 4B | Dose Level 4C |
|---|---|---|---|---|---|---|
| Generalized weaknessMusculoskeletal and connective tissue disorders | 2/3 | 0/4 | 0/3 | 0/2 | 0/4 | 0/4 |
| HypotensionBlood and lymphatic system disorders | 2/3 | 0/4 | 0/3 | 0/2 | 0/4 | 0/4 |
| Neck PainMusculoskeletal and connective tissue disorders | 0/3 | 0/4 | 0/3 | 1/2 | 0/4 | 0/4 |
| Febrile NeutropeniaImmune system disorders | 1/3 | 1/4 | 1/3 | 0/2 | 0/4 | 0/4 |
| PlasmacytomaBlood and lymphatic system disorders | 0/3 | 0/4 | 1/3 | 0/2 | 0/4 | 0/4 |
| Dental InfectionInfections and infestations | 0/3 | 0/4 | 1/3 | 0/2 | 0/4 | 0/4 |
| HypoxiaBlood and lymphatic system disorders | 1/3 | 0/4 | 0/3 | 0/2 | 0/4 | 0/4 |
| Fever, etiology unknownImmune system disorders | 1/3 | 0/4 | 0/3 | 0/2 | 0/4 | 0/4 |
| Upper Resipratory InfectionRespiratory, thoracic and mediastinal disorders | 1/3 | 0/4 | 0/3 | 0/2 | 0/4 | 0/4 |
| IleusGastrointestinal disorders | 0/3 | 1/4 | 0/3 | 0/2 | 0/4 | 0/4 |
| Event | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4A | Dose Level 4B | Dose Level 4C |
|---|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 3/3 | 2/4 | 1/3 | 1/2 | 2/4 | 1/4 |
| Aspartate aminotransferase increasedGastrointestinal disorders | 2/3 | 0/4 | 0/3 | 0/2 | 1/4 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 2/3 | 1/4 | 1/3 | 0/2 | 0/4 | 1/4 |
| Infusion Related ReactionImmune system disorders | 0/3 | 2/4 | 2/3 | 0/2 | 0/4 | 0/4 |
| FatigueGeneral disorders | 1/3 | 2/4 | 0/3 | 0/2 | 0/4 | 0/4 |
| HypoalbuminemiaMetabolism and nutrition disorders | 1/3 | 2/4 | 1/3 | 0/2 | 0/4 | 0/4 |
| ConstipationGastrointestinal disorders | 1/3 | 0/4 | 0/3 | 1/2 | 0/4 | 0/4 |
| DysphagiaGastrointestinal disorders | 1/3 | 0/4 | 0/3 | 1/2 | 0/4 | 0/4 |
| HyperglycemiaMetabolism and nutrition disorders | 1/3 | 0/4 | 0/3 | 1/2 | 1/4 | 1/4 |
| Chronic Kidney DiseaseRenal and urinary disorders | 1/3 | 0/4 | 0/3 | 0/2 | 0/4 | 0/4 |
| Age, Categorical(Participants) | Level 1 Dose | Level 2 Dose | Level 3 Dose | Level 4A | Level 4B | Level 4C | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 2 | 0 | 0 | 1 | 8 |
| >=65 years | 1 | 1 | 1 | 2 | 4 | 3 | 12 |
| Sex: Female, Male(Participants) | Level 1 Dose | Level 2 Dose | Level 3 Dose | Level 4A | Level 4B | Level 4C | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 1 | 2 | 0 | 7 |
| Male | 2 | 2 | 2 | 1 | 2 | 4 | 13 |
| Race/Ethnicity, Customized(participants) | Level 1 Dose | Level 2 Dose | Level 3 Dose | Level 4A | Level 4B | Level 4C | Total |
|---|---|---|---|---|---|---|---|
| White | 3 | 3 | 3 | 2 | 4 | 2 | 16 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Other-Non Hispanic | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| White (Hispanic) | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Region of Enrollment(participants) | Level 1 Dose | Level 2 Dose | Level 3 Dose | Level 4A | Level 4B | Level 4C | Total |
|---|---|---|---|---|---|---|---|
| United States | 3 | 4 | 3 | 2 | 4 | 4 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in May 2021, 21 months.
Results were first posted in Apr 2025, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cartesian Therapeutics